5 Earnings Heroes Poised for Gains Into Late 2026

Earnings season for Q1 2026 is in full swing, with major companies delivering results that separate the strong from the merely adequate. While high-profile names like Tesla, American Express, and Intel grabbed headlines, five other large-cap stocks quietly delivered standout beats on both top and bottom lines.

Below we reveal the 5 earnings heroes – each exceeded expectations and saw positive stock reactions. More importantly, fundamental drivers and technical indicators suggest the post-earnings momentum has the potential to extend well into the second half of 2026 and beyond.

This article provides a deep dive into each company’s Q1 performance, key growth drivers, management guidance, sector context, technical setup, valuation considerations, risks, and long-term investment thesis.

These 5 Stocks Still Have Room to Run in 2026

GE Vernova: Powering the AI and Electrification Megatrend

Q1 2026 Financial Highlights

GE Vernova (NYSE: GEV) delivered a blowout quarter. Revenue came in at approximately $9.34 billion, with orders surging 71% organically to $18.3 billion across all segments. The company’s backlog expanded sequentially by $13 billion to a record $163 billion, boosted by the Prolec GE acquisition. Equipment backlog grew 80% with improved margins.

Free cash flow reached an impressive $4.8 billion in the quarter alone, already exceeding the full-year 2025 total in some metrics.

Backlog Strength and Data Center Demand

The most compelling number was the backlog. Management accelerated its $200 billion backlog target from 2028 to 2027. Electrification booked over $2.4 billion in data center equipment orders in Q1—more than the entire prior year. Gas Power equipment backlog and slot reservations grew from 83 GW to 100 GW, with expectations to reach at least 110 GW by year-end 2026.

This surge reflects exploding electricity demand from AI data centers, grid modernization, and industrial electrification.

Guidance Raise and Margin Expansion

GE Vernova raised full-year 2026 guidance:

• Revenue: $44.5–$45.5 billion (up from $44–$45 billion)
• Adjusted EBITDA margin: 12–14% (up from 11–13%)
• Free cash flow: $6.5–$7.5 billion (up significantly from prior $5.0–$5.5 billion)

Services revenue provided high-margin stability, while equipment margins benefited from better pricing and mix.

Technical Analysis and Momentum

Shares surged 12–17% post-earnings, pushing the stock up over 200% in the last 12 months and roughly 70–75% YTD in 2026. The price continues to find support near the 50-day moving average. RSI remains bullish without extreme overbought readings, while the MACD shows accelerating upward momentum. Volume on the rally was strong, indicating conviction rather than speculation.

Investment Thesis and Risks

GE Vernova sits at the center of two powerful secular trends: AI-driven power consumption and global grid upgrades. The massive backlog provides multi-year visibility, and margin expansion in equipment enhances profitability.

Risks include ongoing losses in the Wind segment (expected to improve in H2), supply-chain execution on large projects, potential moderation in hyperscaler spending, and broader macro factors like interest rates or regulatory delays. Despite these, the visibility from the backlog and raised guidance supports a constructive outlook into late 2026 and 2027.

Intuitive Surgical: Robotic Surgery Reacceleration

Q1 2026 Performance

Intuitive Surgical (NASDAQ: ISRG) reported revenue of about $2.77 billion, up 23% year-over-year, with a significant EPS beat (around 30% upside in key metrics). Recurring revenue, the core of the business, also grew 23%.

Total procedures (da Vinci + Ion) rose ~17%, with da Vinci procedures up 16% to approximately 847,000 and Ion procedures jumping 39%. The company placed 431 da Vinci systems in Q1 (up from 367), including 232 of the newer da Vinci 5 platform, which is showing higher utilization than the prior Xi model.

Procedure Growth and Platform Innovation

Management raised full-year 2026 da Vinci procedure growth guidance to 13.5–15.5%. Growth was broad-based, led by general surgery in the U.S. and international markets outside urology. The da Vinci 5 ecosystem is generating high-fidelity data, setting the stage for future AI-enabled features.

Gross margins remained strong thanks to fixed-cost leverage and product cost reductions, with non-GAAP operating margin around 39%.

Stock Context and Technical Setup

After hitting an all-time high in January 2025, ISRG entered 2026 in a range-bound phase with some YTD pressure. The strong Q1 beat and raised guidance helped shift sentiment. Technical indicators, including MACD and RSI, are turning more constructive after basing, with the stock responding well to positive news.

Long-Term Thesis

Intuitive’s razor-razorblade model creates durable economics through high-margin recurring revenue tied to an expanding installed base (now over 11,000 da Vinci systems). Expansion beyond urology into general surgery, gynecology, thoracic, and the Ion platform for lung procedures broadens the addressable market significantly.

Challenges include hospital capital spending cycles, reimbursement dynamics, competition in certain segments, and geopolitical factors in markets like China. However, rising utilization of the da Vinci 5 and clinical evidence continue to drive adoption.

Masco Corporation: Resilience in Home Improvement

Q1 Results

Masco (NYSE: MAS) posted net sales of $1.918 billion, up 6% year-over-year (4% in local currency). Adjusted EPS rose 20% to $1.04, beating estimates. Gross margin improved to 36.0%, and operating profit increased 13%. The company returned $267 million to shareholders through dividends and share repurchases.

Plumbing Products (led by Delta Faucet) grew 9%, while Decorative Architectural Products were roughly flat but delivered strong profit growth.

Guidance and Operational Focus

Management maintained 2026 EPS guidance ($4.10–$4.30 on an adjusted basis) and continues to emphasize productivity, pricing discipline, and margin expansion.

Technical Perspective

Shares bottomed in March ahead of earnings. Post-report, the stock reclaimed the 50-day and 200-day moving averages. MACD has been trending higher from the lows, and RSI improved, though it is approaching overbought territory that could prompt short-term consolidation.

Investment Case

Masco benefits from repair-and-remodel spending, which tends to be more resilient than new construction. Brand strength (Delta, KraftMaid, etc.), innovation in smart/home products, and cost control support margins even in softer housing environments. Any stabilization in the housing market or interest rate relief could provide additional tailwinds.

Risks center on consumer spending slowdowns, commodity cost volatility, and prolonged high rates impacting home sales and renovations.

Boston Scientific: Signs of a Medtech Reversal

Q1 2026 Highlights

Boston Scientific (NYSE: BSX) generated net sales of $5.203 billion, up 11.6% reported and 9.4% organic. Adjusted EPS reached $0.80 (at the high end of guidance), with broad-based growth across segments. GAAP EPS was $0.90.

Despite the solid beat, the company lowered full-year organic growth guidance to 6.5–8.0% and adjusted EPS to $3.34–$3.41, citing headwinds in electrophysiology, WATCHMAN, and urology.

Why the Stock Rallied Anyway

The Q1 outperformance and progress breaking a long-term downtrend (stock had been down over 30% YTD at points) sparked buying. The move took shares above key moving averages.

Technical Indicators

MACD formed a bullish cross earlier in the year. RSI bounced from oversold levels. After a nearly 40% drawdown from 2025 highs, the setup offers meaningful catch-up potential if the reversal holds.

Thesis and Pipeline Outlook

Boston Scientific’s diversified portfolio in cardiovascular, endoscopy, urology, and neuromodulation provides balance. New product launches and easier comparables are expected to support acceleration into 2027. Margin expansion remains a priority.

Risks include procedure volume softness in specific areas, competitive pressures, and reimbursement or regulatory changes. The significant drawdown creates a higher reward-to-risk profile for patient investors.

Rogers Communications: Capital Discipline Unlocks Value

Q1 Performance

Rogers (NYSE: RCI), the Canadian telecom leader, delivered a top- and bottom-line beat. Service revenue rose 10%, adjusted EBITDA increased 5%, and free cash flow jumped 32% to CAD 776 million, aided by a 17% decline in capital expenditures to CAD 808 million.

Strategic Capex Cut

Management slashed 2026 capital spending guidance by ~30% to CAD 2.5–2.7 billion and raised free cash flow outlook to CAD 4.1–4.3 billion (up ~CAD 800 million). The savings will accelerate debt reduction and support the ~4% dividend yield.

Shares jumped over 13% on the news, reclaiming the 200-day moving average.

Technical Setup

Secondary indicators turned bullish. A sustained move above the 50-day moving average could reignite buying interest. The combination of yield, improved cash flow, and deleveraging appeals to income and value investors.

Investment Thesis

In a capital-intensive industry, shifting from heavy spending to higher free cash flow enhances shareholder returns. Wireless and cable segments offer stability, while media assets provide growth potential. Regulatory and competitive dynamics in Canada remain key watchpoints.

Conclusion: Quality Earnings with Staying Power

These five companies demonstrate varied but compelling paths to post-earnings strength: explosive infrastructure demand at GE Vernova, innovation-led growth at Intuitive Surgical, operational resilience at Masco, potential bottoming in medtech at Boston Scientific, and capital efficiency at Rogers Communications.

Common themes include beats versus consensus, constructive technical setups (support at moving averages, improving MACD/RSI), and management actions that improve visibility or capital returns. While macro risks, execution challenges, and sector-specific headwinds exist, the fundamental and technical evidence points to momentum that could persist through the second half of 2026.

Investors should monitor backlog conversion, procedure trends, cash flow delivery, and any macro shifts in upcoming quarters. As always, perform your own due diligence and consider portfolio suitability. Past performance and analyst targets are not guarantees of future results.

FAQ: 5 Earnings Heroes Poised for Gains Into Late 2026